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Abstract
Background
Discussion whether intravenous tPA or mechanical thrombectomy is the ideal choice for
treatment of acute ischemic strokes has been debated around the medical community for last
three decades. However still, after several clinical trials, it is still unclear if one is superior to the
other.

Methods
This meta-analysis pooled several different results from studies revolving around treatment of
acute ischemic stroke. The goal of this paper was to evaluate whether previous clinical trials
favoring mechanical thrombectomy had sufficient research to prove it is superior to treatment
with tPA in reducing long-term morbidity. Primary outcomes measured were the modified
Rankin scales at 90 days in evaluation of long-term morbidity.

Results
Sixteen different studies were evaluated, six trials evaluating tPA efficacy and ten trials
evaluating mechanical thrombectomy efficacy. Only two out of 6 tPA studies showed positive
benefit, and seven out of ten mechanical thrombectomy studies showed positive benefit.

Conclusion
It is difficult to determine if mechanical thrombectomy is superior to tPA management due to
several confounders and possible study bias in majority of studies showing positive results in
mechanical thrombectomy patients. For example, the majority of positive mechanical
thrombectomy studies and the most common confounder were the studies being stopped early.

which are then susceptible to bias. More studies will need to be conducted, and fully completed,
in order to determine if there is positive benefit over tPA.

Introduction
There has been much debate surrounding the topic of management for acute ischemic stroke
(AIS) patients over the recent decades. The primary therapies debated are whether standard of
care using tissue plasminogen activator (tPA) management, either alone or in conjunction with
direct mechanical thrombectomy (DMT) is superior than direct mechanical thrombectomy
surgery for reducing long term morbidity. Several studies suggest that mechanical thrombectomy
reduced stroke severity, post-stroke morbidity, and improved revascularization rates compared to
treatment with tPA alone for the anterior intracranial circulation, the more common major
intracerebral vessel impacted by AIS 1. However, several other studies suggest that it is unclear
whether or not direct mechanical thrombectomy has added benefit with or without tPA
management for improving post-stroke outcomes.

According to American Heart Association (AHA), every 40 seconds, someone in the United
States has a stroke. That statistic accounts for an incidence of about 795,000 people that suffer
from a new or recurrent stroke each year. Strokes account for the 4th highest cause of death and
the number one cause of morbidity in the United States, where ischemic strokes account for
about 87% of all strokes 2. These statistics prove the importance and relevance of proper
management of this condition in order to reduce both morbidity and mortality.

The management of stroke is dependent on the patient’s symptom presentation, as well as time
and medical institution sensitive. This is important to discuss given that there are important risks
to managing strokes with tPA and/or DMT. For example, tPA has an extensive list of

contraindications including prior stroke in previous 3 months, suspicion of subarachnoid
hemorrhage, history of previous intracranial hemorrhage, or any active bleeding just to list a few.
On the other hand, DMT has a higher risk of symptomatic intracerebral hemorrhage after the
procedure, where the risk factors for this adverse outcome of the procedure are co-morbidities
such as advanced age, high blood glucose, more severe stroke, and pre-existing computerized
tomography (CT) changes 3. However, the overall goal of treatment of stroke is minimize time to
reperfusion in order to prevent further ischemic brain damage, so it is important to determine
what treatment will be beneficial for each patient subgroups while minimizing adverse outcomes
within these groups.

The goal of this paper is to explore the most common treatments for ischemic strokes of the
major cerebral arterial circulation. Furthermore, this paper will aim to determine which treatment
is most beneficial for patients for reducing morbidity as measured by the modified Rankin Scale
(mRS).

Background (Literature Review)
Intravenous thrombolytics, the standard treatment of acute ischemic stroke
Intravenous thrombolytics, including tissue plasminogen activator (tPA) and tenectaplase
(TNKase), has had a long-standing role in the medical community and is considered the “gold
standard” in treatment of AIS. The use of thrombolytics dates back to the 1950’s, however was
not FDA approved until 1996 due to the lack of strong evidence of benefits outweighing the
risks, primarily intracranial hemorrhaging, over that 40-year period 4. It is well known that the
National Institute of Neurological Disorders and Stroke (NINDS) II trial is the primary study that
provided evidence that use of thrombolytics are beneficial in the treatment of AIS. The current

gold standard of care for treatment of AIS is treatment with IV thrombolytics within 4.5 hours of
symptom onset. The following section will explain the thrombolytics mechanism of action, along
with background literature of studies that have evaluated thrombolytics in treatment of AIS.

Before discussing studies surrounding thrombolytic medication treatment of AIS, it would be
appropriate to provide background information about the mechanism of action itself. Since the
majority of studies use tissue plasminogen activator (tPA) as the primary thrombolytic drug, we
will focus on this drug for this discussion. Thrombolytics are serine protease enzymes that cleave
peptide bonds in proteins. It’s primary mechanism of action works by catalyzing the conversion
of plasminogen to plasmin, which is the primary enzyme in dissolving formed clots. This is the
reason the drug is known as a “clot buster” and holds the primary interest of drug choice for
patients with occlusions due to thrombus, such as AIS 5.

Given the relevance of the 1996 NINDS trial and its significant impact on the treatment of AIS
with IV thrombolytics, it would be appropriate to summarize the significance of this clinical trial
within this literature review. During the time before the NINDS trial, promising results from
previous pilot studies from IV thrombolytics increased curiosity to further explore this drug for
specific treatment of AIS. However, given the evidence of increased risk of intracranial
hemorrhaging (ICH) from several of these studies, this large, randomized, double-blind trial was
conducted to determine if the benefits outweigh the risks (ICH) for treatment of AIS. The study
had two parts; part one (NINDS-I) measured changes in neurological deficits 24 hours after the
onset of stroke as a measure of tPA using the National Institutes of Health stroke scale (NIHSS)
and part two (NINDS-II) used four different scales, including the Barthel index, modified Rankin
scale, Glascow outcome scale, and NIHSS, to measure the different aspects of recovery sustained

at 90 days. Part one measured “early improvement”, including complete resolution or
improvement from baseline determined as a 4 or more-point increase on the NIHSS. Part two
measured all patients using the aforementioned four outcome measurement tools at 90 days.
Patients were then grouped by timeframes including 0 to 90 minutes, 91 to 180 minutes, and 0 to
180 minutes after the onset of stroke for both parts. Safety endpoints included intracranial
hemorrhage (ICH), death or other serious adverse effects and were screened using CT scans at 24
hours, 7 to 10 days following onset of stroke, or symptoms suggestive of ICH. Eligibility for
participation included clearly defined time marker for stroke onset, clearly measureable deficit
using NHISS, and no evidence of intracranial hemorrhage on noncontrast CT scan. NINDS-I had
a total of 291 patients enrolled and NINDS-II had a total of 333 patients enrolled.
Contraindications to randomization included head trauma within 3 months, major surgery within
the last 14 days, history of intracranial hemorrhage, systolic blood pressure above 185mmHg or
diastolic blood pressure above 110mmHg, rapidly improving symptoms, symptoms of
hemorrhage including subarachnoid, GI, or urinary tract within the previous 21 days, had a
seizure with symptom onset, or patients taking anticoagulants within 48 hours on stroke onset 6.
The results of this study can be further explored in the discussion section of this paper.

Other studies studying thrombolytics have tried to determine whether there is benefit of
thrombolytic therapy within different timeframes of administration. There were several studies
conducted shortly after the NINDS trial evaluating different timeframes of the efficacy of
thrombolytics following the onset of symptoms. The European Cooperative Acute Stroke Study
(ECASS) conducted three, the ECASS 1, ECASS 2, and ECASS 3 trials in 1995, 1998, and
2008, respectively. Other studies that looked at timeframe includes the Alteplase Thrombolysis
for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS), ATLANTIS A and

ATLANTIS B trials. The ATLANTIS trials, however, were essentially the same trial split
between modifications mid-trial due to safety concerns. These details will be discussed below.

ECASS-I evaluated 620 patients with signs of acute ischemic changes on noncontrast CT and
were randomized to receive 1.1 mg/kg of rt-PA (alteplase) or placebo within 0-6 hours of onset
of symptoms. The primary outcomes were evaluated with the Barthel Index and modified Rankin
scale at 90 days, with secondary outcomes including a combined Barthel Index and Rankin scale,
Scandinavian Stroke Scale at 90 days and 30-day mortality. Tertiary outcomes included early
neurologic recovery. The results of this study can be further explored in the discussion section of
this paper 7.

ECASS-II evaluated 800 patients in Europe, Australia, and New Zealand with early ischemic
signs on noncontrast CT without signs of major infarction. Patients were stratified for time for
symptom onset of either 0 to 3 hours or 3-6 hours.

Patients were randomly assigned 0.9mg/kg

rt-PA alteplase or placebo, resulting in 409 and 391 patients, respectively. The primary outcome
was a modified Rankin scale at 90 days dichotomized for a favorable outcome of score 0-1 vs
unfavorable outcome of score 2-6. The results of this study can be further explored in the
discussion section of this paper 8.

ECASS-III was a randomized, double-blind, parallel-group trial that evaluated 821 patients
around multiple centers in Europe to determine if there were beneficial effects of administering
tPA in patients with AIS between 3 and 4.5 hours after symptom onset. Patients were evaluated
clinically with noncontrast CT scan for signs of early AIS and excluded if CT showed signs of
ICH or major infarction. Once inclusion criteria were met, patients were randomly assigned in
1:1 double-blind fashion to receive either 0.9mg/kg IV tPA or placebo. The primary outcome

measurement used the mRS at 90 days to evaluate for favorable outcome, defined as a score of 0
or 1 vs unfavorable outcome of score 2-6. Safety endpoints included symptomatic ICH, death
and other serious adverse effects 9. The results of this study will be further explored in the
discussion section of this paper.

ATLANTIS A trial was a randomized, double-blind trial that began in August 1991 and again
evaluated the efficacy and safety of intravenous rtPA for 142 patients with AIS within 6 hours of
onset. The study consisted of a randomized, double-blind administration of rtPA for patients
aged 18-80 years old with clearly defined time marker for stroke onset, clearly measureable
deficit using NHISS, and no evidence of intracranial hemorrhage on noncontrast CT scan,
similar to the NINDS trial criteria. The intervention group was given of 0.9mg/kg IV rtPA split
between a 10% IV bolus over the first 1-2 minutes followed by the remaining delivered by
infusion over the next 1 hour. The primary efficacy outcomes of this study measured as “good
outcomes” were a 4 or more point decrease on the NIHSS scale at 24 hours and 30 days, as well
as infarct volume measured by noncontrast CT scan at day 30 at 24+/- 6 hours and at 30+/-7
days. The secondary outcomes measured were by mortality, Barthel Index and Modified Rankin
scale at 30 and 90 days. Safety parameters were measured by the blinded independent data safety
monitoring board (DMSB), which measured overall mortality, asymptomatic intracranial
hemorrhaging (ICH), symptomatic ICH, fatal ICH, and other serious adverse effects on an
ongoing basis during the study. The results of this study can be further explored in the discussion
section of this paper 10.

ATLANTIS B trial was a randomized, double-blind, multicenter, placebo-controlled
clinical trial conducted between 1993 and 1998, further evaluating a more efficacious timeframe

for administering rtPA. This was part of the same ATLANTIS trial mentioned above, however
due to safety concerns for patients receiving rtPA >6 hours, the investigators modified the study
to evaluate the specific time of rtPA resulting in the ATLANTIS “B” trial we discuss here. The
study inclusion criteria are the same as the ATLANTIS A trial mentioned above. The total
amount of patients enrolled was 613 between both parts of the study. The intervention group was
given of 0.9mg/kg IV rtPA split between a 10% IV bolus over the first 1-2 minutes followed by
the remaining delivered by infusion over the next 1 hour. The outcomes of this trial were the
same as the ATLANTIS A trial. ATLANTIS B trial, however, heavily focused on safety
measurements, starting at baseline and monitored closely through 90 days. Neurologic symptoms
and hemorrhaging symptoms were evaluated by the NIHSS scale at baseline, 120 minutes, 24
hours, and 7, 30 and 90 days. Barthel Index, Modified Rankin scale and Glascow outcome scale
at 30 and 90 days were also used for evaluation of these symptoms. Vital signs were monitored
at 24 hours and were maintained below 185/110mmHg following administration of the drug.
Clinical laboratory tests were also used to monitor patient status, measuring a complete blood
cell count, coagulation tests, and fibrinogen and fibrin degradation products at baseline, 6 hours,
and 24 hours following administration. Noncontrast CT scan were also performed at baseline, 6
hours and 24 hours, 23 days and 37 days, or sooner is patient showed signs of neurological
deterioration for assessment of intracranial hemorrhaging, infarct signs and size of infarct10. The
results of this study can be further explored in the discussion section of this paper.
The largest study, in terms of total patients, ever conducted that evaluated the benefits of IV
thrombolytics in treatment of AIS was the 3rd installment of the International Stroke Trial (ISTIII). IST-III was an open-label, international, multicenter, randomized, controlled trial that
explored the benefits of tPA within 6hours of symptom onset. A total of 3035 patients from 12

different countries were enrolled in this trial. Eligible patients had presented with a known time
of symptom onset and could start of treatment within 6 hours. Patients were also excluded if they
showed signs of ICH or any structural brain lesions on CT or MRI. Patients were randomized
upon confirmation of eligibility and the intervention grouped would receive 0.9mg/kg plus
standard care vs the control being standard care alone, of which the article did specifically
mention what was included in “standard care”. The total number in each group was intervention
group, 1515 and control group, 1520. The primary outcomes evaluated patients using the Oxford
handicap scale, which is essentially identical to the modified Rankin scale 34, of which a
favorable outcome was measured as a score of 0-2 at 6 months. Secondary outcomes measured
multiple areas at 18 months following treatment including; overall survival, Oxford handicap
score, health-related quality of life, overall functioning, and living circumstances 11. Results from
this trial will be further explored in the discussion section of this paper.

The use of thrombolytics as the “gold standard” treatment is essentially based on these trials
previously discussed. More than 20 years following the NINDS trial, studies have tried to look
again at the benefits of thrombolytics in the treatment of AIS. Due to the extensive nature of
adverse effects of thrombolytics and the new emergence of DMT, studies have tried to focus
more on determining which patient populations could benefit more with less adverse effects
instead of utilizing thrombolytics on the majority of patients with symptoms of stroke. Due to the
advancement of technology, these studies have looked more closely at which patient populations
could benefit from tPA using advanced imaging and will be discussed later in the paper.

Endovascular therapy

Before discussing studies surrounding this approach to endovascular treatment of AIS, this
paper will provide background information about the procedure itself. Endovascular or intraarterial therapy (IAT) is a relatively new treatment approach that was achieved in 2008 and
refers to a catheter-based approach to physical disruption of a clot, locally injected thrombolytic
agents, such as tPA, or both in conjunction. arteries 12. The stent-like thrombectomy devices,
now called stent-retriever, are the primary catheters used for the procedure today 13. IAT are
currently only used for large artery occlusion in the basilar, distal carotid, or proximal middle
cerebral arteries 12. The procedure to disrupt the clot includes two possible techniques; the stent
retriever technique and the aspiration technique, and can be done under general anesthesia with
intubation or conscious sedation.

The stent retriever technique involves entering the target occluded vessel, most commonly
beginning at the carotid artery, with a 0.014-inch guidewire and microcatheter between 0.018
and 0.027 inch followed by a stent retriever device with sizes that can range from 3.0x15mm to
6.0x30mm depending on which vessel is occluded. The guidewire is pushed through the
thrombus and the microcatheter is placed distally to the thrombus. Then, the stent retriever
device is advanced distal to the thrombus where the guidewire and microcatheter are then
removed, allowing for the stent retriever device to expand and “capture” the thrombus, which
can be seen on fluoroscopy evidenced by spontaneous return of partial blood flow. After a short
period of time, the device is pulled back with continuous aspiration and negative pressure to
prevent further disruption of the clot (Figure 7). Outcome of the procedure is measured by the
Thrombolysis in Cerebral Infarction (TICI) score, which is repeated until a score of 2b or 3 is
reached 14. The TICI score measures the response to reperfusion therapy measured by
angiographic appearance of the occluded vessel. The grading is a scale of 0-3; grade 0, no

perfusion; grade 1, penetration with minimal perfusion; grade 2, partial perfusion subgrouped
into A and B which characterized by amount and speed of filling; and grade 3, complete
perfusion 15. Although this treatment is still new to the AIS world, endovascular therapy has
shown promising results in the treatment of AIS as well as negative results.

The aspiration technique is an alternative technique used for patients undergoing endovascular
therapy but present with unique situations. These situations include occlusions located in the
internal carotid artery, middle cerebral artery bifurcation and trifurcation, or hard thrombi
configuration. This technique begins similarly to the stent retrieval device technique, where the
catheter is inserted near the occluded vessel. However, unlike the retrieval stent, the guidewire,
microcatheter and aspiration catheter are placed into the proximal part of the thrombus. The
thrombus is essentially sucked in through the aspiration catheter, where entrapment of the
thrombus is indicated by the absence of backflow. The aspiration catheter is then retrieved using
constant negative pressure to ensure capture of the thrombus avoid loss or breakage of any part
of the thrombus. Success of the procedure is indicated by a TICI grade of 2 or 3 16(Figure 8).

Perhaps the most influential trial regarding thrombectomy in treatment of AIS was the MR
CLEAN trial conducted in 2015. The trial was a pragmatic, multicenter, randomized, open-label
trial that consisted of 500 adult patients with clinical signs of AIS. Inclusion criteria included
symptom onset within 6 hours and signs of ischemic stroke specifically in the anterior
circulation; distal internal carotid, middle cerebral artery, or anterior cerebral artery, confirmed
by CTA or MRA. The intervention group would receiver intra-arterial treatment (IAT),
consisting of either direct mechanical thrombectomy, intra-arterial thrombolysis or a
combination of both, which was left to the interventionist. IAT dose was given as a maximum

dose of 90mg of tPA or 1,200,000 IU of urokinase, and the dose was restricted to 30mg or
400,000 if already given IV tPA, respectively. Mechanical thrombectomy procedures included
retrievable stent, aspiration, thrombus retraction or wire disruption. The comparison group
consisted of intravenous tPA alone. Primary outcomes measured the mRS score at 90 days,
categorized as an “improved excellent outcomes” as a mRS score of 0-1 and “improved
functional independence” as a mRS score of 0-2. Safety outcomes also measured mortality and
symptomatic intracerebral hemorrhaging, measured by imaging not specifically mentioned. The
results of this study can be further explored in the discussion section of this paper.

There are several other studies using endovascular therapy that were conducted similarly to the
MR CLEAN study. EXTEND IA, ESCAPE, SWIFT PRIME and REVASCAT are all separate
trials published in 2015 that also explored the benefits of endovascular therapy vs tPA alone,
similar to the MR CLEAN trial. There were only slight differences between these trials and the
MR CLEAN trials, such as different imaging to screen patients and specified occluded vessels
for eligible patients. For example, the EXTEND IA trial used CT perfusion to measure for
salvagable brain tissue and would only trial IAT for patients with ICA or MCA occlusion 18. The
ESCAPE trial used CTA to screen for specifically proximal MCA occlusion (with or without
ICA occlusion) and good collateral circulation, indicated by >50% filling of MCA circulation
territory 19. SWIFT PRIME used “vessel imaging” to confirm occlusion anywhere in the
proximal anterior intracranial circulation with absence of large vessel ischemic cores 20.
REVASCAT used any “neuroimaging” to confirm occlusion in proximal anterior circulation and
selected patients were either ineligible to receive tPA or had not recanalized within 30 minutes of
IV tPA administration. Another component of this study included interventionalists had to have
performed at least 60 mechanical thrombectomies in their careers in order to perform the

operation 21. Unfortunately, all of these trials were stopped early either because of a prespecified
boundary for stoppage of the trial, lack of efficacy, or equipoise results to the MR CLEAN trial.
More specific results will be further explored in the discussion section of this paper.

Three recent trials explored the benefits of combining IV tPA with mechanical thrombectomy
vs IV tPA alone for patients with large vessel occlusion. The THRACE trial conducted in
consisted of a total of 414 patients from 26 different centers in France and were randomized
based on inclusion criteria of neurological defect with confirmed ischemic findings on either
CTA or MRA. In order to qualify for IV tPA, patients had to present with a known symptom
onset within 4 hours, and in order to qualify for the MT, patients had to present within 5 hours of
symptom onset. Patients received IV tPA at 0.9mg/kg administered as 10% bolus followed by
the remaining 90% dose given over the next hour, with a maximum dose of 90mg for patients
>100kg. Primary outcomes were measured by functional independence, defined as a mRS score
of 0-2 at 90 days 22. The THERAPY trial conducted in 2016 and was essentially the same trial in
regards to inclusion criteria, intervention vs control groups and primary outcomes. The only
difference was that THRACE specifically used aspiration mechanical thrombectomy in their
intervention group (in addition to IV tPA). The results of these trials will be explored in the
discussion section of the paper.

The third study that explored the benefits of combining IV tPA with mechanical
thrombectomy vs IV tPA alone for patients with large vessel occlusion was the SKIP
Randomized Clinical trial. This trial was an investigator-initiated, multicenter, randomized,
open-label, no inferiority clinical trial that evaluated 204 patients in Japan with acute ischemic
stroke due to large vessel occlusion. Although this trial is very similar to the trials previously

discussed, this trial wanted to explore if a lower dose of tPA is essentially “needed” in
combination of mechanical thrombectomy. The author specifically wanted to address whether
mechanical thrombectomy alone is “non-inferior” to combined intravenous thrombolysis using
0.6-mg/kg. The eligibility criteria for this study was much more extensive than previous studies;
aged 18 to 85 years old, acute stroke with findings of ICA or MCA occlusion on CTA or MRA,
Alberta Stroke Program score of 6 to 10, DWI ASPECTS score of 5-10, an initial NIHSS score
equal to or greater than 6, and mRS score of 0-6 before symptom onset. The patients must also
have met eligibility criteria of the “Japanese guidelines for treatment with lower dose of
0.6mg/kg tPA within 4.5 hours of symptom onset”, which were the exact same as the NINDS
trial. The intervention group had a total of 101 patients and received mechanical thrombectomy
alone, where the control group had a total of 103 patients and received a combination of
mechanical thrombectomy with 0.6mg/kg IV tPA. The primary outcomes included favorable
outcome measured by mRS score of <2 on at 90 days 23. The results of this study can be further
explored in the discussion section of this paper.

Three studies conducted in 2013 also explored the efficacy of endovascular therapy compared
to tPA alone, including one study that directly compared DMT to tPA without combination
therapy (MR RESCUE). These three studies were SYNTHESIS, IMS 3 and MR RESCUE and
will be outlined below.

The SYNTHESIS trial was a pragmatic, multi-center, randomized, open-label trial that
consisted of 362 randomly assigned patients to receive either endovascular therapy, IV tPA or a
combination of both. Eligible patients with a definitive time of onset of symptoms received
imaging to confirm AIS findings as well as rule out intracranial hemorrhaging. All patients who

presented within 4.5 hours of symptom received randomization to either IV tPA or endovascular
therapy, and patients who presented within 6 hours of symptoms were enrolled into the
intervention group. IV tPA dose was given immediately following randomization at a dose of
0.9mg/kg administered as 10% bolus followed by the remaining 90% dose given over the next
hour, with a maximum dose of 90mg. Endovascular therapy consisted of disintegration of the
thrombus through micro-guidewire, stent retrieval devices, or aspiration technique. Patients in
the intervention group that showed a neurological deficit, measured using the NIHSS, with no
corresponding occlusion received IAT tPA into the presumably affected area. The dose was the
same as IV tPA. The primary outcome measured mRS score at 90 days, recognizing a favorable
outcome as a score of 0-1. Safety outcomes measured intracranial hemorrhaging and mortality 24.
The results of this study can be further explored in the discussion section of this paper.

The IMS 3 trial was a multicenter, randomized, open-label trial that evaluated the benefit of
performing endovascular therapy following administration of tPA. A total of 656 patients were
randomized in a 2:1, intervention to control, ratio with signs of major cerebral vessel occlusion.
The criteria for this trial to receive intervention was dependent on whether the patient had a large
cerebral vessel occlusion, however the eligibility criteria in this trial was majority based on an
NIHSS score of >10, which indicated a >80% likelihood of a major arterial occlusion on
subsequent angiography based on the results of a different study conducted 25. Later in the trial,
amendment 3 to eligibility protocol, and after 284 patients had already enrolled, identification of
occluded vessels with CTA as allowed to determine eligibility for intervention. All participants
with a symptom onset within 3 hours would receive the standard dose of tPA on arrival;
0.9mg/kg administered as 10% bolus followed by the remaining 90% dose given over the next
hour, with a maximum dose of 90mg for patients >100kg. Randomization would take place

within 40 minutes after the initiation of the infusion, where patients in the intervention group
would receive 2/3 of the standard dose and patients in the control group would receive a full
standard dose of tPA. The intervention group would then confirm with angiography imaging.
Angiography would have to confirm evidence of treatable occlusion to receive further
endovascular treatment, which was up to the discretion of the interventionist. Operations
included thrombectomy, revascularization device, or an endovascular delivery of tPA. The
primary outcomes included favorable outcome measured by mRS score of <2 on at 90 days. The
intervention group used the TICI score following procedures 26. The results of this study can be
further explored in the discussion section of this paper.

MR RESCUE was a phase 2, multicenter, randomized, open label trial that evaluated whether
patterns on imaging could predict therapeutic outcome with different treatment approaches such
as, in this case, standard care with tPA or mechanical embolectomy. 118 total patients with
stroke symptom onset within 8 hours were randomized to receive either mechanical
embolectomy or standard medical care. Eligibility criteria included symptom onset within 8
hours and an NIHSS score of 6 to 29 (out of a score of 42), and showed signs of large-vessel
occlusion in the anterior circulation on either CTA or MRA. All patients received either CT or
MRI at baseline in order for stratification based on the presence of “favorable penumbral
pattern”, which was defined as a predicted infarct core size of 90mL or less and predicted
infarcted tissue within the at-risk region was 70% or less. The intervention group was treated
with all FDA-approved devices at the time including the Merci Retriever, a stent retrieval device,
Penumbra system, a reperfusion and aspiration device, as well as intra-arterial tPA for “emergent
use” if revascularization was not achieved within 6 hours after symptom onset. The control
group received standard care, however the article does not mention the specific dose of tPA. The

primary outcomes wanted to evaluate specifically if the presence of a favorable penumbral
pattern would benefit more with mechanical embolectomy as compared to standard of care.
Primary outcome measurements were mRS score, however the article does not mention time
frame of measurement. Secondary outcomes measured TICI score at 7 day imaging follow up
with CR or MRI, and was considered successful reperfusion if there was a reduction of 90% or
more in the volume of perfusion lesion 27. The results of this study can be further explored in the
discussion section of this paper.

Imaging in AIS

Imaging is one of the most important modalities providers have to detect ischemic changes of
the brain in conjunction clinical presentation. The American College of Radiology (ACR)
continually updates its guidelines through the ACR Appropriateness Criteria regarding imaging
modalities for patients presenting with acute neurodeficits with suspected stroke, both less than
and greater than 6 hours since symptom onset. According to these guidelines, the ACR
Appropriateness Criteria provides evidence-based guidelines to assist referring providers in
making the most appropriate imaging and management decisions for specific clinical situations.
The following section will discuss the different imaging modalities used for evaluation of AIS as
well as common findings seen with different imaging modalities.

Rapid evaluation of strokes is necessary to provide quick decision making when managing a
patient with stroke symptoms. A noncontrast computed tomography (CT) scan is the primary
imaging modality for the initial evaluation of patients with suspected stroke according to the
ACR (ACR, 2009). Noncontrast CT scans are primarily used because the scan is quick and since
blood will be seen as hyperattenuation, or bright white, in acute strokes, signifying a

concentrated area of blood. Findings on noncontrast CT scans are also able to help distinguish
timeframe of ischemic changes and are typically divided into three main stages; acute stroke
(less than 24 hours), subacute stroke (24 hours to 5 days), and chronic (weeks to months). Other
terminology used for acute stroke are “early ischemic changes” or “hyper-acute changes”. Acute
ischemic changes cause intracellular edema and causes loss of normal gray matter and white
matter interface, termed “differentiation”. It also causes central sulci effacement which is
representative of a local secondary sign of mass effect on the brain parenchyma, thus displacing
the cerebrospinal fluid to push the adjacent gyri together 28 (Figure 1) Subacute changes are
represented by vasogenic edema with greater mass effect, and can be seen as hypoattenuation
and well-defined margins on CT scans. (Figure 2) However, as time goes on and intracranial
swelling goes down and small amounts of cortical petechial hemorrhaging occurs, this can
actually produce a hyperattenuating effect, also known as the “CT fogging phenomenon”. This
can often be a misleading representation due to the brain tissue often looking “normal” (Figure
3). Chronic changes can be represented by complete loss of brain tissue and are hypoattenuating
on CT scans. The damaged necrotic tissue is reabsorbed which results in encephalomalcia, which
can be described as blurred cortical margins and decreased brain tissue consistency consistent
with gliosis of adjacent brain tissue (Figure 4). Noncontrast CT scans are also used to rule out
other etiologies that may present similarly to acute ischemic strokes. Examples of other
etiologies include intracerebral hemorrhaging, intraparenchymal hematomas, intracerebral
abscess, and tumors.

Once there is confirmed ischemic changes on noncontrast CT scan, the next imaging modality
typically used is the computer tomography angiogram (CTA). The CTA provides is a minimally
invasive imaging study that requires a time optimized rapid injection of intravenous contrast at

the same time as thin-section helical CT images are obtained during the arterial phase. These
thin-sectional axial CT images enable the viewer a more complete view of the cerebral
vasculature real time (Figure 5), where the three-dimensional reformations provide an even
clearer image of the cerebral vessels. This imaging can evaluate the circulation beginning at the
aortic arch through the entire Circle of Willis, often performed in under 60 seconds. This
imaging is effective at identifying specifically where the clot is within the cerebral blood vessels
in rapid fashion. This is especially important because the advanced imaging gives providers more
information inside the body in conjunction with the clinical presentation to make the most
appropriate decisions regarding the management. CTA can also utilize the clot burden score
(CBS), which is a 10-point scoring system that quantifies the extent of the thrombus within the
anterior cerebrovascular circulation, specifically looking at the major anterior circulation
including the middle cerebral artery (M1) and anterior cerebral artery (A1). The scoring system
works by subtracting two points for a thrombus preventing opacification on CTA in the proximal
M1, distal M1, or supraclinoid internal carotid artery (ICA) and one point subtracted for a
thrombus preventing opacification for M2 branches, A1 and infraclinoid internal carotid artery
(Figure 6). A score of 10 indicates no thrombus where a score of 0 indicates complete
multisegment vessel occlusion, where a higher score was typically more associated with
increased odds of independent functional outcomes 29. Different parameters such as symptom
onset and area of occluded artery, helps providers determine which medical intervention would
be most beneficial. Furthermore, these parameters can assist interventional neuroradiologists and
neurosurgeons in planning operations and procedures.

Noncontrast magnetic resonance imaging, or standard “MRIs”, are not as favorable for
detecting acute strokes (<24 hours) as CT scans. MR imaging can take up to an hour to perform

which is obviously not favorable when treatment of stroke requires rapid protocol, however are
“usually appropriate” according to the ARC (ACR, 2009). Unfortunately, standard noncontrast
MRIs are not very good at detecting cytotoxic and intracellular edema, a primary finding in acute
strokes of less than 24 hours. However, noncontrast MRIs do a good job of detecting vasogenic
edema. Vasogenic edema is a primary sign in subacute strokes, which are typically greater than
24 hours. Fluid attenuated inversion recover (FLAIR) is a type of MR imaging sequence that was
designed to suppress CSF imaging signal, essentially to appear black not interfere with details of
the brain tissue itself. It is especially useful in detecting subarachnoid hemorrhages, which will
appear bright white, and is typically used in the initial evaluation of AIS patients if suspected.
MR diffusion imaging, or diffusion weight images (DWI), is a fascinating way that uses MR
imaging to detect ischemic changes. DWI can be performed in as little as 10 minutes and works
by measuring the “weight”, or motion of water molecules within the brain. Uninjured celled will
distribute equal amounts of water between neuronal cells, but during the cytotoxic injury to these
neuronal cells during an ischemic event, water accumulates within the injured cells without the
ability to diffuse out as quickly as healthy cells. According to one study, once a hemorrhagic
stroke has been ruled out, MR diffusion improves the detection of acute ischemic stroke from
50% (with CT) to more than 95% 28. In order to specifically detect the area of ischemia, DWI
uses an apparent diffusion coefficient (ADC) map which essentially confirms the area of
restricted water diffusion in order to get an accurate diagnosis. During regular DWI imaging,
areas of “high signal” will appear bright white, but can be misleading from other “high signal”
fluid such as vasogenic edema. ADC imaging allows providers to recognize areas that are not
secondary to acute infarct where impacted areas will appear dark with ADC 30 (Figure 7).

The shift from “time is brain” to “imaging is brain”

One of the most common sayings in medicine is that “we should not treat all patients the
same”, but this could not be truer when it comes to the management of acute stroke patients. It is
becoming clearer to providers and researchers alike that imaging may provide a better idea of
which reperfusion therapy may be more beneficial for different patient presentations. Imaging
has recently become a primary focus in clinical trials when trying to determine the most effective
therapy in the treatment of AIS, especially in more recent thrombolytic clinical trials.
Incorporation of advanced imaging to determine what treatment works for patients with
salvageable brain tissue may allow for better clinical decisions making while decreasing the
adverse effects of chosen treatments. More recent research is trying to answer these questions
and will be discussed within this section of the paper.

The WAKEUP trial was a multicenter, randomized, double-blind placebo-controlled trial
conducted in 2018 that evaluated whether MRI guided IV thrombolysis could be beneficial for
patients with an unknown symptom onset, such as waking up from sleep with stroke symptoms
or 4.5 hours since they were last seen well-appearing in health, such as symptoms of aphasia or
confusion. Eligibility of the study included patients 18 to 80 years old who had been able to
carry out activities of daily living independently before their stroke. The study used two different
imaging modalities within the MRA to determine eligibility for the study, the diffusion weighted
imaging (DWI) and standard window settings on fluid-attenuated inversion recover (FLAIR).
Eligible patients had findings of an acute ischemic lesion on DWI but no parenchymal hyper
intensity on FLAIR and were selected upon the investigator’s discretion. The chosen imaging
was due to the suspected stroke occurring approximately in the last 4.5 hours. Eligible patients
would then receive 0.9mg/kg of alteplase (rtPA), administered as 10% bolus followed by the
remaining 90% dose given over the next hour, where the intervention group was compared with

a placebo. A total of 503 were patients enrolled in the study, where 254 patients randomly
received the rtPA and 249 received placebo. Excluded patients included patients undergoing
planned thrombectomy operation, intracranial hemorrhaging on MRI, lesions greater than 1/3 of
the territory of the MCA, and contraindications to alteplase. Primary outcomes measured were
measured as “favorable clinical outcomes”, measured by a score of 0 to 1 on the modified
Rankin scale. Secondary outcomes also measured efficacy based on combined scores of mRS
and NIHSS, including a mRS score of 0 with NIHSS score <7, a mRS score of 0 to 1 with
NIHSS score of 8 to 14, and mRS score of 0 to 2 with NIHSS score of >14. Secondary
outcomes also included a global outcome score at 90 days measured with four scales; mRS,
NIHSS, Barthel Index, and Glasgow Outcome Scale. A “good outcome” consisted of a mRS and
NIHSS score of 0 to 1, a Barthel Index score of 95 to 100, and an overall Glascow Outcome
Scale score. Clinical assessments included the recording of demographic information, medical
history including concurrent medications, laboratory values, scores on the NIHSS scale and
modified Rankin scale, and assessment of adverse effects. A standard brain MRI was also
included in clinical assessment to monitor for ICH and infarct volume, measured at 22 to 36
hours after randomization. The primary safety end points evaluated were death and “poor
outcomes”, which were measured by a mRS score of 4 to 6 at 90 days. Secondary safety end
points utilized the aforementioned clinical assessment MRI imaging at 22 to 36 hours after
randomization to evaluate for symptomatic ICH and incidence of parenchymal hematoma type 2,
and were evaluated by an independent ventral safety-adjudication committee by members
unaware of the trial 31. This study essentially tried to determine if there were specific timing
parameters, determined by ischemic changes on MRI, that could help determine beneficial
administration of thrombolytics in AIS patients after the standard of care time frame.

Unfortunately, the study was stopped early due to cessation of funding, however the results of
this study can be further explored in the discussion section of this paper.

More recent studies have tried to examine whether imaging can help determine if
administration of tPA is beneficial for patients after 4.5 hours, the standard of care timeframe for
treatment of AIS with tPA. The primary study was the fourth rendition of the European
Cooperative Acute Stroke Study (ECASS), labeled as the ECASS4-EXTEND trial, which
wanted to further explore if imaging could help determine if tPA is beneficial for patients after
4.5 hours of symptom onset. The study was an investigator driven, phase 3, randomized, multicenter, double blind, placebo-controlled study. The patient eligibility included patients
presenting with AIS symptom onset of 4.5 to 9 hours or upon waking up without definitive
symptom onset timeframe with acute neurological deficit, quantified as a 4-26 NIHSS score, and
pre-stroke mRS score of 0-1. Eligible patients then would undergo MRI scanning. Imaging
eligibility criteria for randomized treatment then included findings of infarct core volume of
<100mL, perfusion lesion characterized as an infarct core mismatch ratio >1.2, and perfusion
lesion minimum volume of 20mL. The intervention group would receive 0.9 mg/kg tPA with a
10% IV bolus followed by the remaining through infusion over 1 hour. Primary outcomes
measured as favorable outcomes included a mRS score of 0 to 1 at 90 days following treatment.
Secondary and tertiary outcomes included disability at day 90, NIHSS reduction of 11 or more
points, recanalization at 24 hours post stroke, depression and life quality. Safety outcomes
included symptomatic intracranial hemorrhaging and mortality 32. The results of this study can be
further explored in the discussion section of this paper.

Methods

The data discussed in this research paper came from an extensive search using credible
databases such as PubMed, Google Scholar, New England Journal of Medicine (NEJM) and the
National Center for Biotechnology Information (NCBI). Many of these databases directed to
studies conducted by credible Search terms for relevant vocabulary and information about
subjects included “tPA”, “mechanical thrombectomy”, “stroke standard of care”, “endovascular
therapy”, “modified Rankin scale”, and “stroke imaging”. Background information was also
explored using credible medical websites such as REBELEM.com. This website is an emergency
medicine-based blog that includes frequent reviews of emergency medicine related clinical trials
as well as a podcast that includes discussion points about clinical trials, unique cases in the
emergency department, or other general discussion about emergency medicine topics.

Discussion
The results of the previously discussed trials will be discussed during this section of the paper.
The structure of this discussion will focus on discussing positive versus negative studies, defined
as studies showing a benefit vs studies showing no benefit or lacks evidence to support benefit.
Positive and negative studies will be grouped together accordingly. The majority of the primary
outcomes from each study evaluated a mRS score at 90 days and will be the primary focus of
these discussion results, however additional or different primary outcomes will be mentioned if
applicable to the study. The main topic of this paper is trying to compare and contrast each
treatment approach, either mechanical thrombectomy or standard care with tPA, to determine
which may be more beneficial in decreasing long-term morbidity in patients following AIS. The
results from these articles will be used to compare and contrast these different therapeutic
approaches in order to determine if any one therapy is more beneficial for reducing long-term
morbidity.

Before exploring the results of the previously discussed clinical trials, it would be beneficial to
define the different outcome measurement scores that these studies use. The Barthel index is a
reliable scoring system that measures the ability to perform activities of daily living (ADL) such
as eating, bathing, grooming, dressing, bowel control, bladder control, toilet use, bed to chair and
back transfers, mobility and stairs. Scores are variable with each ADL but in summary
independent receives a full score of 10, assistance needed receives a 5, and dependent receives a
0. All scores added up will determine the overall score, where a score of 100 is considered
completely independent 33. The modified Rankin scale is an overall assessment of function in
which a score of 0 indicates the absence of symptoms, score of 1-5 indicate severity of disability,
and a score of 6 indicates death 34. The Glasgow outcome scale a global assessment of function
in which a score of 1 indicates a good recovery; a score of 2 indicates moderate disability; a
score of 3 indicates severe disability; a score of 4 indicates survival but in a vegetative state; and
a score of 5 indicates death 35. The NIHSS was specifically developed for the NINDS trial and is
a serial measure of neurologic deficit that uses a 42-point scale that quantifies neurologic deficits
into 11 categories. NIHSS determines the patients level on consciousness and attention by asking
the patient questions and asking them to perform simple tasks. For example, asking the patient
their own age and what month it is; answering both questions right would be 2 points, one
question right is 1 point, and neither is 0 points. Further exploration of motor and sensory
function through extensive tests such as extraocular eye movement, “squeezing hands”, visual
fields, facial palsy, arm motor drift, leg motor drift, ataxia, overall sensation, language/aphasia,
and dysarthria 36. The global test statistic is a proposed equation that allows researchers to
evaluate several different performance categories or measurement tools, and make overall
statements based off those components of related importance 37.

tPA results

There have been two studies in the last 30 years that showed positive benefit for tPA use in the
treatment of AIS, the NINDS-II and ECASS-III trials. NINDS-I showed no significant
improvement, however it’s primary outcome was measured with NIHSS score at 90 days.
NINDS-II used the previously discussed four outcome scales and did show significant
improvement in all four categories at 90 days. Both parts of the studies were combined together
and evaluated all four outcome measurements, both at 0-90 minutes, 91-180 minutes, and 0-180
minutes. For the specific purpose of this discussion, the NINDS-I did not show significant
improvement of mRS score at 90 days in patients receiving tPA (Figure 9). The NINDS-II trial
showed favorable outcomes in 39% of patients receiving tPA versus 26% in patients receiving
placebo on mRS score at 90 days, with an odds ratio of 1.7 (Figure 10). The ECASS-III trial
evaluated a different timeframe for administration of tPA that was previously discussed, the
timeframe specifically being between 3 and 4.5 hours. ECASS-III showed favorable outcomes in
52.4% in patients receiving tPA vs 45.2% in patients receiving placebo, with an odds ratio of
1.34.

The following studies have been deemed as negative trials, including ECASS-1, ECASS-II,
ATLANTIS, and IST-III. ECASS-1, however, did show a significant improvement in mRS at 90
days, resulting in favorable outcomes of 35.8% of patients receiving tPA versus 22.3% of
patients receiving placebo (Figure 12). ECASS-2 results showed favorable mRS scores in 40.3%
of patients receiving tPA versus 33.6% of patients receiving placebo, resulting in statistically
insignificant findings. The ATLANTIS trial(s) results showed favorable mRS scores in 34% of
patients receiving tPA versus 32% of patients receiving placebo, resulting in statistically

insignificant findings. The IST-III trial results showed favorable OHS scores at 6 months in 37%
of patients receiving tPA versus 35% of patients receiving placebo, resulting in statistically
insignificant findings.

The other two studies evaluated the benefits of using tPA in conjunction with more advanced
imaging modalities; WAKE UP and EXTEND. The WAKE UP trial showed favorable mRS
scores in 53.3%% of patients receiving tPA versus 41.8% of patients receiving placebo.
Unfortunately, the trial was stopped early due to cessation of funding after the enrollment of 503
patients of the anticipated 800 patients. The EXTEND trial showed favorable mRS scores in
35% of patients receiving tPA versus 29% of patients receiving placebo. Unfortunately, this trial
was also stopped due to cessation of funding after the enrollment of 225 patients of the
anticipated 310 patients.

Overall, using mRS data from all the studies, intervention with tPA produced a 36.65% benefit
compared to 32.57% benefit with control (Table 1). These statistics argue that treatment with
tPA is statistically insignificant as compared to placebo. These statistics can conclude that tPA
may have an advantage in treatment of AIS, however more studies need to be done to evaluate
for efficacy.

Endovascular results

The following 3 studies are slightly different than the subsequent studies in that imaging
(CTA or MRA) was not done to definitively prove proximal occlusion when patients presented
with symptoms of stroke. Also, since these trials were older, the subsequent trials used more
technologically advanced stent retrievers in their trials. SYNTHESIS showed favorable mRS

scores in 30.4% of patients receiving endovascular therapy versus 34.8% of patients receiving
systemic IV tPA alone, showing statistically insignificant results. The IMS-III trial showed
favorable mRS scores in 40.8% of patients receiving endovascular therapy versus 38.7% of
patients receiving systemic IV tPA alone. However, this trial was stopped early due to futility of
the study. MR RESCUE evaluated a mean mRS score at 90 days which resulted in mean score of
3.9 for both the embolectomy group and standard care with tPA group, showing statistically
insignificant results.
The following trials did require inclusion criteria of proximal vessel occlusion seen on
CTA or MRA, essentially utilizing more advanced technology that the previously discussed trials
did not have access to. MR CLEAN showed favorable mRS scores in 44.2% of patients in the
endovascular therapy group versus 25.1% of patients receiving standard of care with tPA. Of
note, 89% of all patients were treated with IV tPA before randomization. EXTEND IA showed
favorable mRS scores in 71% of patients in the endovascular therapy group versus 40% of
patients receiving standard of care with tPA. ESCAPE showed favorable mRS scores in 53% of
patients in the endovascular therapy group versus 29.3% of patients receiving standard of care
with tPA. However, this trial was stopped early due to efficacy. SWIFT PRIME showed
favorable mRS scores in 60% of patients in the endovascular therapy group versus 35% of
patients receiving standard of care with tPA. However, this trial was stopped early at 196
patients. Of note, the trial was also funded by Covidien, the maker of the Solitaire retriever
which could indicate bias. REVASCAT showed favorable mRS scores in 43.7% of patients in
the endovascular therapy group versus 28.2% of patients receiving standard of care with tPA.
Unfortunately, this trial was also stopped early at 206 patients instated of the anticipated 690
patients, again minimizing magnitude of the results. Of note, this study was also funded by

Covidien as well. THRACE showed favorable mRS scores in 53% of patients in the combined
endovascular therapy and tPA group versus 42% of patients receiving standard of care with tPA.
Unfortunately, this study was also stopped early, resulting in a total of 414 patients. Of note,
mRS scores were estimated by neurologists that were not blinded to treatment arms. THERAPY
showed favorable mRS scores in 38% of patients in the endovascular therapy group versus
30%% of patients receiving standard of care with tPA, which was statistically insignificant. This
trial was also stopped early and thus impacts power of the study results. SKIP trial favorable
mRS scores in 57.3% of patients in the combination endovascular and tPA group versus 59.4%
of patients receiving standard of care with tPA.
Overall, using mRS data from all the studies, intervention with endovascular treatment
produced a 43.58%% benefit compared to 32.59% benefit with control (Table 2). These statistics
argue that treatment with endovascular remedies is statistically significant and could be debated
that it is a better option as compared to placebo. These statistics can conclude that endovascular
therapy may have an advantage in treatment of AIS, however more studies need to be done to
evaluate for efficacy.
Conclusion

The debate of treatment of AIS still remains strong today. There have been many important
studies that have tried to evaluate the best approach to treatment of AIS, however, based on the
studies discussed in this paper and the scientific community overall. Although many of the
studies discussed show promising results, the data to support an efficacious treatment still
remains unclear.

The use of tPA has long been a debated subject in the treatment of AIS and after doing
extensive research on this drug, it is easy to see why. The studies discussed in this paper do not
show extensive evidence as to legitimate efficacy for treatment of AIS. It is also hard not to
analyze these studies to see that there could be many confounding interests that potentially leave
room for bias in writing the results. However, although tPA has not distinctively proven its
efficacy, it is still the standard treatment approach to stroke.

Endovascular therapy is a promising new way for treatment of stroke, however, it is difficult to
determine if it is, in fact, superior to tPA. The studies discussed in this paper are also very much
susceptible to bias after further analyzing the results. One obvious confounder to these studies is
that several studies were stopped early, drastically impacting the magnitude of benefit for
patients receiving endovascular therapy. More studies need to be done and fully completed in
order to determine if endovascular therapy is as beneficial as these studies result in.

There is a large gap in the years of publication for the studies discussed in this paper, however,
the use of advanced imaging has made an impact on researching this topic at greater detail.
Rather than administering tPA or performing endovascular therapy on patients with symptoms of
stroke, researchers are trying to use technological advances in imaging modalities to determine
who may benefit for either therapy. Moving forward, focusing on these confounders in future
studies may be the most necessary in order to determine which therapy will be most beneficial.
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Appendix

Figure 1:
Axial noncontrast computer tomography shows hypoattenuating foci through the left sided white
matter (arrows) and sulcal effacement in the left MCA consistent with acute ischemic changes 38.

Figure 2:
Axial noncontrast computer tomography 24 hours after symptom onset showing a hypodense
area and enlargement of the left temporal lobe 39.

Figure 3:
Axial noncontrast computer tomography taken at 36 hours (left image) and 18 days (right
image). Left image shows occipital hypodensities consistent with infarction, where the right
image shows isodense appearance of previous infarction, also known as the “fogging
phenomenon” 40.

Figure 4:
Axial noncontrast computer tomography demonstrating chronic ischemic stroke changes in the
right temporal lobe, also known as encephalomalacia 39.

Figure 5:
Axial computer tomography angiogram showing occlusion of the right anterior cerebral artery 41.

Figure 6:
Figure demonstrating the clot burden score, including the regions within the circulation with its
corresponding subtracted value. From proximal to distal two point subtractions; proximal M1
middle cerebral artery (MCA), and distal M1 MCA. supraclinodial ICA, From proximal to distal
one point subtractions; M2 middle cerebral artery (MCA), anterior cerebral artery (A1), and
infraclinodial internal carotid artery (ICA) 42.

Figure 7:
MR diffusion showing a right MCA occlusion. Box A) DWI imaging shows area with increased
signal intensity consistent with area of right MCA occlusion. Box B) ADC imaging shows area
with decreased signal intensity consist with right MCA occlusion 28.

Figure 7:
A) Angiography showing an acute middle cerebral artery occlusion with placement of stent
retriever device. The distal end of the stent retrieval device (white arrow); the thrombus is
pressed to the vessel wall (black arrows) with spontaneous partial flow restoration. B) Successful
recanalization of the artery as evidence by complete restoration of blood flow. C) Stent retrieval
device is retracted thrombus D) MRI imaging showing infarction size following EVT (white
arrow) 14.

Figure 8:
Endovascular thrombectomy with the aspiration technique in acute ischemic stroke. A) CT
angiography showing acute occlusion of the distal middle cerebral artery (white arrow), B)
placement of an aspiration catheter proximally to thrombus (white arrow). C and D) Parts of
thrombus material within the aspiration tube following retrieval (white arrows). E) CT
angiogram shows successful recanalization and restoration of circulation after primary aspiration
technique14.

Table 1
Table comparing results of mRS score among studies evaluating efficacy of tPA as
interventional treatment versus control groups.

Table 2
Table comparing results of mRS score among studies evaluating efficacy of endovascular
treatment as interventional treatment versus to control groups.
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